Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
9.35
+0.26 (2.86%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 18.22, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 94.87% from the current stock price of 9.35.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lexeo Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $19 | Buy | Initiates | $19 | +103.21% | Dec 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $19 | Buy | Initiates | $19 | +103.21% | Nov 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +81.82% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +39.04% | Oct 21, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +220.86% | Oct 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.56
from -3.09
EPS Next Year
-2.04
from -2.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.09 | -1.18 | ||||
| Avg | -2.56 | -2.04 | ||||
| Low | -3.23 | -2.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.